{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:08:36Z","timestamp":1792692516362,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.therap.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T12:27:11Z","timestamp":1519216031000},"page":"715-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Safety data and withdrawal of hepatotoxic drugs"],"prefix":"10.1016","volume":"76","author":[{"given":"Samy","family":"Babai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Auclert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Le-Lou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004221","article-title":"An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making","volume":"15","author":"McNaughton","year":"2014","journal-title":"BMJ Open"},{"issue":"17","key":"10.1016\/j.therap.2018.02.004_bib0260","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2174\/138161210791208910","article-title":"In vitro evaluation of potential hepatotoxicity induced by drugs","volume":"16","author":"Gomez-Lechon","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.therap.2018.02.004_bib0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00204-006-0091-3","article-title":"High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening","volume":"80","author":"O\u2019Brien","year":"2006","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2042098610386281","article-title":"Drug-induced liver injury in older adults","volume":"1","author":"Mitchell","year":"2010","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.therap.2018.02.004_bib0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3350\/cmh.2012.18.3.249","article-title":"Drug-induced liver injury: present and future","volume":"18","author":"Suk","year":"2012","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.therap.2018.02.004_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40290-013-0015-5","article-title":"Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed. Perspectives of a clinical hepatologist","volume":"27","author":"Lewis","year":"2013","journal-title":"Pharm Med"},{"key":"10.1016\/j.therap.2018.02.004_bib0285","series-title":"U.S.\u00a0Department of health and human services. Drug-induced liver injury: premarketing clinical evaluation","first-page":"28","year":"2009"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0290","article-title":"Are animal models predictive for humans?","volume":"15","author":"Shanks","year":"2009","journal-title":"Philos Ethics Humanit Med"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0295","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0273-2300(05)80057-1","article-title":"Harmonization of guidelines for toxicity testing of pharmaceuticals by 1992","volume":"12","author":"Speid","year":"1990","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0305","first-page":"227","article-title":"DILI and drug development: regulatory perspective","volume":"34","author":"Regev","year":"2014","journal-title":"Seminar in liver disease"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0310","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2016.8.1.3","article-title":"Update on advances in research on idiosyncratic drug-induced liver injury","volume":"8","author":"Kim","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/bmm.13.146","article-title":"Toward predictive models for drug-induced liver injury in humans: are we there yet?","volume":"8","author":"Chen","year":"2014","journal-title":"Biomarkers Med"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0320","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4254\/wjh.v9.i1.30","article-title":"Drug-induced liver injury: towards early prediction and risk stratification","volume":"8","author":"Raschi","year":"2017","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0325","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hep.20514","article-title":"Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin","volume":"41","author":"Liguori","year":"2005","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.therap.2018.02.004_bib0330","doi-asserted-by":"crossref","first-page":"e0184744","DOI":"10.1371\/journal.pone.0184744","article-title":"HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity","volume":"12","author":"Lundgren","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.therap.2018.02.004_bib0335","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat Genet"},{"issue":"9435","key":"10.1016\/j.therap.2018.02.004_bib0340","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.therap.2018.02.004_bib0345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0350","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the diabetes prevention program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.therap.2018.02.004_bib0355","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ng0810-650","article-title":"Preempting and preventing drug-induced liver injury","volume":"42","author":"Aithal","year":"2010","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.therap.2018.02.004_bib0360","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2018.02.004_bib0365","series-title":"LiverTox. Clinical and research information on drug-induced liver injury 2018","year":"2018"},{"issue":"3","key":"10.1016\/j.therap.2018.02.004_bib0370","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v3i3.269","article-title":"Withdrawing drugs in the U.S. versus other countries","volume":"3","author":"Ninan","year":"2012","journal-title":"Inov Pharm"},{"key":"10.1016\/j.therap.2018.02.004_bib0375","article-title":"COMT inhibitors and liver toxicity","volume":"55","author":"Watkins","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.therap.2018.02.004_bib0380","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00002018-200326110-00001","article-title":"Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy","volume":"26","author":"Borges","year":"2003","journal-title":"Drug safety"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNF.0000000000000008","article-title":"Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study","volume":"37","author":"Eggert","year":"2014","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"10.1016\/j.therap.2018.02.004_bib0390","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00204-016-1845-1","article-title":"Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man","volume":"90","author":"Dragovic","year":"2016","journal-title":"Arch Toxicol"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0395","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1572-0241.2003.07175.x","article-title":"Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone","volume":"98","author":"Graham","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.therap.2018.02.004_bib0400","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00003495-199957030-00014","article-title":"Troglitazone a review of its use in the management of type 2 diabetes mellitus","volume":"57","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.therap.2018.02.004_bib0405","series-title":"Unhealthy pharmaceutical regulation. Innovation, politics and promissory science","author":"Davis","year":"2013"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0410","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1207","article-title":"A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience","volume":"15","author":"GoldkindL","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0415","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/toxsci\/kfn056","article-title":"In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone","volume":"103","author":"Dykens","year":"2008","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0420","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kfj095","article-title":"Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone","volume":"90","author":"Kostrubsky","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.therap.2018.02.004_bib0425","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","article-title":"Drug-induced liver injury in humans: the case of ximelagatran","volume":"196","author":"Keisu","year":"2010","journal-title":"Handb Exp Pharmacol"},{"issue":"45","key":"10.1016\/j.therap.2018.02.004_bib0430","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.3748\/wjg.v16.i45.5651","article-title":"Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage?","volume":"16","author":"Bessone","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0435","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/tx8002356","article-title":"Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts","volume":"22","author":"Kang","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.therap.2018.02.004_bib0440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1183\/09031936.00058409","article-title":"Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension","volume":"34","author":"Lavelle","year":"2009","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0445","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/path.1711350407","article-title":"Furosemide induced hepatotoxicity","volume":"135","author":"Walker","year":"1981","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0450","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0773.1990.tb00840.x","article-title":"Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor)","volume":"67","author":"Horsmans","year":"1990","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.therap.2018.02.004_bib0455","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vascn.2013.08.001","article-title":"A high content screening assay to predict human drug-induced liver injury during drug discovery","volume":"68","author":"Persson","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.therap.2018.02.004_bib0460","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","article-title":"Probability of adverse events that have not yet occurred: a statistical reminder","volume":"311","author":"Eypasch","year":"1995","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.therap.2018.02.004_bib0465","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","article-title":"Drug-induced liver disorders: implications for drug development and regulation","volume":"24","author":"Kaplowitz","year":"2001","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.therap.2018.02.004_bib0470","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2018.02.004_bib0475","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1353\/pbm.1968.0004","article-title":"The spectrum of hepatotoxicity","volume":"12","author":"Zimmerman","year":"1968","journal-title":"Perspect Biol Med"},{"issue":"4","key":"10.1016\/j.therap.2018.02.004_bib0480","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.therap.2018.02.004_bib0485","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/lt.500050607","article-title":"Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation","volume":"5","author":"Fontana","year":"1999","journal-title":"Liver Transpl Surg"},{"issue":"2","key":"10.1016\/j.therap.2018.02.004_bib0490","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tasmar advisory panel. Tolcapone and hepatotoxic effects","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.therap.2018.02.004_bib0495","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.286.7.831","article-title":"Liver enzyme monitoring in patients treated with troglitazone","volume":"286","author":"Graham","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2018.02.004_bib0500","article-title":"Piazza-Hepp. Spontaneous reporting\u2013USA","author":"Graham","year":"2002"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718300362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718300362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:21Z","timestamp":1758567321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718300362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0040595718300362"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.02.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety data and withdrawal of hepatotoxic drugs","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}